ARTICLE | Product Development
Targeting obesity
March 26, 2007 7:00 AM UTC
Phase II anti-obesity agents are attacking the disease via multiple paths. A number of compounds are suppressing appetite by affecting neurotransmitters dopamine, noradrenaline, serotonin and histamin...